Biorez Appoints Jeff Grebner as Director of Clinical Affairs
Sports medicine veteran brings over 20 years of leadership experience in clinical strategy and clinical evidence generation
NOVEMBER 01, 2021
Biorez Inc., a New Haven, late-stage start-up advancing tendon and ligament healing, today announced the appointment of Jeff Grebner as Director of Clinical Affairs. Grebner joins the Biorez team at an opportune time as the company hits key clinical and procedural milestones with its proprietary BioBrace Implant technology in 2021.
“Jeff is a thoughtful clinical leader with extensive relationships and experience managing end-to-end pre and post-market evidence generation initiatives from concept through completion and publication,” said Kevin Rocco, Founder and CEO of Biorez. “He developed and managed the clinical study plans for three prior successful medical device startups that were acquired in transactions totaling over $1 billion. Jeff was also a key member of the Rotation Medical team, where he orchestrated the generation of post-market clinical data that drove market adoption for their regenerative implant for rotator cuff repair leading to a successful acquisition and transition to Smith & Nephew.”
Grebner brings more than 20 years of clinical affairs experience at both large and small companies. Most recently, he served as Head of Clinical Development with Philips Hospital Patient Monitoring and has held senior clinical management roles with Smith & Nephew / Rotation Medical and Entellus Medical.
“I’m passionate about the potential for the BioBrace technology to improve tendon and ligament healing and have been impressed with initial clinician feedback,” said Grebner. “I look forward to partnering with orthopedic and sports medicine health care professionals to deliver robust evidence to further demonstrate the value of BioBrace.”
CONMED Completes Acquisition of Biorez, Inc.AUGUST 09, 2022
Biorez Announces David Hook as Vice President of Sales as it Prepares for BioBrace® CommercializationMAY 05, 2021
Biorez Preclinical Results to be Featured in Podium Presentation at The Orthopaedic Summit: Emerging Technologies 2020DECEMBER 07, 2020
Biorez™ Raises $3.5 Million to Close Out $7 Million in Seed FinancingSEPTEMBER 09, 2020
Biorez Hosts Grand Opening Celebration at District in New HavenDECEMBER 19, 2018
© Biorez 2022. All rights reserved.